Amgen Inc (AMGN): Today's Featured Health Care Laggard
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
(
) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.4%. By the end of trading, Amgen fell $7.83 (-6.9%) to $104.93 on average volume. Throughout the day, 7,425,231 shares of Amgen exchanged hands as compared to its average daily volume of 5,203,400 shares. The stock ranged in price between $104.02-$108.37 after having opened the day at $106.67 as compared to the previous trading day's close of $112.76. Other companies within the Health Care sector that declined today were:
(
), down 22.0%,
(
), down 11.2%,
(
), down 10.0% and
(
), down 9.9%.
- EXCLUSIVE OFFER: Jim Cramer's Protege, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $85.0 billion and is part of the drugs industry. The company has a P/E ratio of 20.5, above the S&P 500 P/E ratio of 17.7. Shares are up 31.6% year to date as of the close of trading on Tuesday.
TheStreet Ratings rates Amgen as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Amgen Ratings Report.
On the positive front,
(
), down 17.6%,
Sucampo Pharmaceuticals Inc. A
(
), down 16.7%,
(
), down 11.7% and
(
), down 9.6% , were all gainers within the health care sector with
(
) being today's featured health care sector leader.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider
Health Care Select Sector SPDR
(
) while those bearish on the health care sector could consider
ProShares Ultra Short Health Care
(
).
- Find other investment ideas from our top rated ETFs lists.
Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null
